Assefa Muluneh, Amare Azanaw
Department of Medical Microbiology, School of Biomedical and Laboratory Sciences, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia.
Infect Drug Resist. 2022 Aug 31;15:5061-5068. doi: 10.2147/IDR.S379502. eCollection 2022.
Biofilm-related multi-drug resistance (MDR) is a major problem in hospital-acquired infections (HAIs) that increase patient morbidity and mortality rates and economic burdens such as high healthcare costs and prolonged hospital stay. This review focuses on the burden of bacterial biofilm in the hospital settings, their impact on the emergence of MDR in the HAIs, biofilm detection methods, recent approaches against biofilms, and future perspectives. The prevalence of biofilm-associated MDR among HAIs ranges from 17.9% to 100.0% worldwide. The predominant bacterial isolates causing HAIs in recently published studies were , A. , and . In addition to the use of qualitative and quantitative methods to detect biofilm formation, advanced PCR-based techniques have been performed for detecting biofilm-associated genes. Although there are suggested therapeutic strategies against biofilms, further confirmation of their efficacy for in vivo application and antibiotics targeting biofilm-associated genes/proteins to minimize treatment failure is required for the future.
生物膜相关的多重耐药性(MDR)是医院获得性感染(HAIs)中的一个主要问题,它会增加患者的发病率和死亡率以及经济负担,如高昂的医疗费用和延长的住院时间。本综述聚焦于医院环境中细菌生物膜的负担、它们对医院获得性感染中多重耐药性出现的影响、生物膜检测方法、针对生物膜的最新方法以及未来展望。在全球范围内,医院获得性感染中生物膜相关多重耐药性的患病率在17.9%至100.0%之间。在最近发表的研究中,导致医院获得性感染的主要细菌分离株是 、 以及 。除了使用定性和定量方法检测生物膜形成外,还采用了基于PCR的先进技术来检测生物膜相关基因。尽管有针对生物膜的治疗策略建议,但未来还需要进一步确认它们在体内应用的疗效以及针对生物膜相关基因/蛋白质的抗生素,以尽量减少治疗失败。